SCM
REGN icon

Solas Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Solas Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,218
Closed -$10.2M – 24
2025
Q3 		$10.2M Sell
18,218
-376
-2% -$213K 6.25% 6
2025
Q2 		$9.76M Buy
+18,594
New +$10.4M 5.46% 9

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Solas Capital Management's REGN Position: Q4 2025 in Review

Solas Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 18,218 shares — an estimated $10.2M sold.

Solas Capital Management first reported a position in REGN in Q2 2025 and held it in 2 quarters. The position peaked at $10.2M in Q3 2025. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Solas Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Solas Capital Management sold 18,218 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $10.2M.
  • Solas Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Solas Capital Management's Regeneron Pharmaceuticals position peaked at $10.2M in Q3 2025.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Solas Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.